# Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma

> **NCT00625183** · PHASE2 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 5 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** selenomethionine
- **DRUG:** capecitabine
- **DRUG:** oxaliplatin
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study
- **PROCEDURE:** adjuvant therapy
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00625183
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2009-10
- **Final completion:** 2009-12
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Withdrawn due to poor/low accrual
- **Last updated:** 2017-11-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00625183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00625183, "Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00625183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*